Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 2 | Immunity & Ageing

Fig. 2

From: IL-17A promotes the progression of Alzheimer’s disease in APP/PS1 mice

Fig. 2

IL-17Ab ameliorated the decrease in spatial and working memory in APP/PS1 mice. A Schematic of IL-17A or IL-17Ab administration to APP/PS1 mice via intraperitoneal injection. B Escape latency of APP/PS1 mice injected with IL-17A or IL-17Ab during the training phase of the MWM test. n = 5 for each group. C1-40 levels in the brain tissues of APP/PS1 mice after the injection of IL-17A or IL-17Ab. D1-42 levels in the brain tissues of APP/PS1 mice after the injection of IL-17A or IL-17Ab. E Representative immunofluorescence images of Aβ plaques in APP/PS1 mice after the injection of IL-17A or IL-17Ab. The values are expressed as the mean ± standard deviation (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05). The data are representative of at least three independent experiments

Back to article page